SciClone Pharmaceuticals (Holdings) Limited 6600.HK Stock
SciClone Pharmaceuticals (Holdings) Limited Price Chart
SciClone Pharmaceuticals (Holdings) Limited 6600.HK Financial and Trading Overview
Contents
- SciClone Pharmaceuticals (Holdings) Limited Price Chart
- SciClone Pharmaceuticals (Holdings) Limited 6600.HK Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of SciClone Pharmaceuticals (Holdings) Limited
- Q&A For SciClone Pharmaceuticals (Holdings) Limited Stock
SciClone Pharmaceuticals (Holdings) Limited stock price | 18.06 HKD |
Previous Close | 10.64 HKD |
Open | 10.58 HKD |
Bid | 10.76 HKD x N/A |
Ask | 10.78 HKD x N/A |
Day's Range | 10.58 - 10.94 HKD |
52 Week Range | 5.65 - 12.38 HKD |
Volume | 620.5K HKD |
Avg. Volume | 1.78M HKD |
Market Cap | 6.66B HKD |
Beta (5Y Monthly) | 0.439093 |
PE Ratio (TTM) | 8.166666 |
EPS (TTM) | 1.86 HKD |
Forward Dividend & Yield | 0.39 (3.76%) |
Ex-Dividend Date | June 2, 2023 |
1y Target Est | 12.22 HKD |
6600.HK Valuation Measures
Enterprise Value | 5.39B HKD |
Trailing P/E | 8.166666 |
Forward P/E | 6.5731707 |
PEG Ratio (5 yr expected) | -3.86 |
Price/Sales (ttm) | 2.420928 |
Price/Book (mrq) | 2.4312134 |
Enterprise Value/Revenue | 1.96 |
Enterprise Value/EBITDA | 4.118 |
Trading Information
SciClone Pharmaceuticals (Holdings) Limited Stock Price History
Beta (5Y Monthly) | 0.439093 |
52-Week Change | 34.85% |
S&P500 52-Week Change | 20.43% |
52 Week High | 12.38 HKD |
52 Week Low | 5.65 HKD |
50-Day Moving Average | 11.12 HKD |
200-Day Moving Average | 8.92 HKD |
6600.HK Share Statistics
Avg. Volume (3 month) | 1.78M HKD |
Avg. Daily Volume (10-Days) | 1.26M HKD |
Shares Outstanding | 617.51M |
Float | 268.94M |
Short Ratio | N/A |
% Held by Insiders | 47.69% |
% Held by Institutions | 15.19% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.345 |
Trailing Annual Dividend Yield | 3.24% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.2455 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 31.10% |
Operating Margin (ttm) | 43.85% |
Gross Margin | 75.29% |
EBITDA Margin | 47.61% |
Management Effectiveness
Return on Assets (ttm) | 17.97% |
Return on Equity (ttm) | 32.21% |
Income Statement
Revenue (ttm) | 2.75B HKD |
Revenue Per Share (ttm) | 4.08 HKD |
Quarterly Revenue Growth (yoy) | 7.39% |
Gross Profit (ttm) | 2.07B HKD |
EBITDA | 1.31B HKD |
Net Income Avi to Common (ttm) | 855.36M HKD |
Diluted EPS (ttm) | 1.32 |
Quarterly Earnings Growth (yoy) | 7.50% |
Balance Sheet
Total Cash (mrq) | 2.64B HKD |
Total Cash Per Share (mrq) | 3.92 HKD |
Total Debt (mrq) | 852.63M HKD |
Total Debt/Equity (mrq) | 28.5 HKD |
Current Ratio (mrq) | 4.039 |
Book Value Per Share (mrq) | 4.434 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.18B HKD |
Levered Free Cash Flow (ttm) | 377.42M HKD |
Profile of SciClone Pharmaceuticals (Holdings) Limited
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Central Plaza |
ZIP | N/A |
Phone | 86 21 2319 3800 |
Website | https://www.sciclone.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 990 |
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
Q&A For SciClone Pharmaceuticals (Holdings) Limited Stock
What is a current 6600.HK stock price?
SciClone Pharmaceuticals (Holdings) Limited 6600.HK stock price today per share is 18.06 HKD.
How to purchase SciClone Pharmaceuticals (Holdings) Limited stock?
You can buy 6600.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SciClone Pharmaceuticals (Holdings) Limited?
The stock symbol or ticker of SciClone Pharmaceuticals (Holdings) Limited is 6600.HK.
Which industry does the SciClone Pharmaceuticals (Holdings) Limited company belong to?
The SciClone Pharmaceuticals (Holdings) Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does SciClone Pharmaceuticals (Holdings) Limited have in circulation?
The max supply of SciClone Pharmaceuticals (Holdings) Limited shares is 615.57M.
What is SciClone Pharmaceuticals (Holdings) Limited Price to Earnings Ratio (PE Ratio)?
SciClone Pharmaceuticals (Holdings) Limited PE Ratio is 9.70967700 now.
What was SciClone Pharmaceuticals (Holdings) Limited earnings per share over the trailing 12 months (TTM)?
SciClone Pharmaceuticals (Holdings) Limited EPS is 1.86 HKD over the trailing 12 months.
Which sector does the SciClone Pharmaceuticals (Holdings) Limited company belong to?
The SciClone Pharmaceuticals (Holdings) Limited sector is Healthcare.